Reza Rahbar-Semnani, MD
Colon & Rectal Surgery · Rockport, MENPI 1952540247
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Mimedx Group, Inc. at 33.1% of the total.
Across 19 payments — averaging $30.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mimedx Group, Inc.$190
- Johnson & Johnson$66
- Merck$56
- Covidien LP$56
- Integra Lifesciences Corporation$49
- Medtronic$30
- plus $127 from 7 others
What the payments were for
- Food & beverage$55597%
- Education$183%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mimedx Group, Inc. | 1 | $190 |
| Johnson & Johnson | 2 | $66 |
| Merck | 4 | $56 |
| Covidien LP | 1 | $56 |
| Integra Lifesciences Corporation | 1 | $49 |
| Medtronic(2 entities) | 2 | $30 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $24 |
| Vioptix Inc | 1 | $20 |
| Baxter Healthcare | 1 | $18 |
| Biomerieux Inc | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| AbbVie | 1 | $16 |
| La Jolla Pharmaceutical Company | 1 | $14 |
How this compares
Too few colon & rectal surgery providers in Maineto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GattexTeduglutide | 12 | $537,581 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 27 | $4,818 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 55 | $3,572 |
| Colestipol Hcl | 15 | $2,460 |
| Neomycin Sulfate | 78 | $419 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 23 | $377 |
| Metronidazole | 97 | $322 |
| Ondansetron Hcl | 73 | $144 |
| Oxycodone Hcl | 33 | $95 |
| Promethazine Hcl | 18 | $42 |
| Meloxicam | 13 | $22 |
| Tramadol Hcl | 19 | $15 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Rockport
- Jerald HurdleWaterville$17K
- Marie AudettPortland$9K
- Joseph MackPortland$8K
- Kathreen LeePortland$5K
- Brian GillisOakland$3K
- Richard StockwellWestbrook$1K
- Melville RobertsPortland$820
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.